-+ 0.00%
-+ 0.00%
-+ 0.00%

Scinai shifts R&D focus to NanoAb platform, targets €12 million Poland grant for IL-17 psoriasis program

PUBT·09/08/2026 13:20:00
Listen to the news
Scinai shifts R&D focus to NanoAb platform, targets €12 million Poland grant for IL-17 psoriasis program
  • Scinai shifted R&D spending to its NanoAb platform, ending further funding commitments tied to the PC111 program.
  • Capital allocation will prioritize NanoAb development, partnering options, and non-dilutive financing, while preserving management capacity for CDMO execution.
  • Two IL-17 NanoAb programs remain core near-term priorities, including a psoriasis grant bid seeking EUR 12 million to reach first-in-human readiness.
  • CDMO growth stays central, targeting about USD 5 million of 2026 revenue, supported by about USD 3.1 million of committed orders.
  • Work began on an expanded U.S. customer clinical manufacturing and CMC program, with a broader definitive agreement targeted in coming weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scinai Immunotherapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN42353) on September 08, 2026, and is solely responsible for the information contained therein.